Rebut...Opko Health: Shorting Is The Best Diagnosis [View article] Gee, that's a pretty long article about what you think about OPKO and all the reasons why you took a short position on OPK. But I am long OPK, and think that some of those "reasons" that you enumerate, are probably why so many other people also decided to take a short position on OPK and OPK is now one of the largest "Short Traps".
According to the data in Yahoo, as of last month, there are more than 33 millions short shares, which is about 24.10% of the float, and it would take more than 23 trading days, or more than 4 weeks at the current average volume, if all the shorts wanted to cover.
I don't want to make too long a comment, but since your article is long,lets just look at some of your points.
You Said: "Operationally, the Claros device remains unproven. Numerous questions surround just how profitable the Claros system will turn out to be." However, Technology Review commented: "Claros uses microfluidics technology, which allows for the manipulation of fluids on a chip at microscopic scales, to develop inexpensive, easy-to-use diagnostic devices that can be deployed at the point of care, whether in a doctor's office or at a patient's bedside. Those tests get results quickly without having to be sent out to a lab for analysis and allow physicians to track certain disease-related markers more often and more thoroughly. The market for point-of-care diagnostics could potentially be huge because of the benefits it offers. Patients benefit from getting results at the time of their visit; doctors and insurers benefit from a less complicated process with less overhead. Claros's prostate-cancer test has been approved for use in Europe, and the company is currently seeking approval to market it from the U.S. Food and Drug Administration." And OPKO has said that the more specific PSA test they have developed after the novel biomarkers they licensed from Arctic Partners could avoid more than 60% of biopsies that are been done on "false postive" results of the current PSA test. They wil be also expect to market a Vitamin D and Folic Acid test this year. To have a better answer to your question of "how profitable the Claros system will be", better look at the slides of the latest presentation, which are still available at OPKO's web page.
Regarding the Molecular Diagnostics, You said: "Simply put, Kodadek's tests did not identify a biomarker, which is the minimum of what Opko would need in order to create a commercially viable diagnostic blood test." However, James M. Anderson, M.D., Ph.D., director of the National Institutes of Health (NIH) Division of Program Coordination, Planning, and Strategic Initiatives , has a much different opinion, since he said: "Dr. Kodadek has conceived a new approach for identifying antibody biomarkers of human disease that bypasses the conventional, but difficult, step of identifying the natural antigens or antigen mimics. The results in the paper suggest great potential for using this approach to rapidly develop diagnostic biomarkers for a variety of significant human diseases. Such boldness to challenge conventional paradigms to achieve important scientific advances is a hallmark of the NIH Director's Pioneer Award Program, which supported much of this research." http://bit.ly/MAnNwk
Concerning Dr. Phillip Frost, You said: "Frost has had some successes, but he has had plenty of spectacular failures." But apparently wirh only "some successes" and "plenty of spectacular failures" he became a billionaire and those that invested with him became multimillionaires.
You also said: "In my opinion. Frost's historical track record is very patchy.", and that you plan to write a future article that will elaborate on why you believe it's a mistake to invest in OPK because Frost is purchasing the stock. But before you write that future article, it seems you probably should read a little about Dr. Frost, so that your future article won't have as many inaccuracies as the present one. This article on Wikipedia could be one for you to start reading: Phillip Frost MD Biography at Wikipedia: http://bit.ly/KrgwVr
On this other article at Bloomberg-BusinessWeek, on OPKO.where there is also a list of Dr.Frost's "Board Memberships and "Other Affiliations", that may be of help to you: http://bit.ly/MAnNwn
And we better not make any comments on many other OPKO's assets, since you didn't mention any of those on your long tirade and diatribe of OPKO For example, FineTech, which through its FDA registered facility in Nesher, Israel, manufactures commercial APIs for sale or license to pharmaceutical companies in the United Sates, Canada, Europe and Israel. Or CURNA, which is engaged in the discovery of new drugs for the treatment of a variety of illnesses, including cancer, heart disease, metabolic disorders and a range of genetic anomalies.
News 
Market Data 
Discover 
AI
